MedPath
HSA Approval

EYLEA SOLUTION FOR INJECTION 114.3 MG/ML

SIN17040P

EYLEA SOLUTION FOR INJECTION 114.3 MG/ML

EYLEA SOLUTION FOR INJECTION 114.3 MG/ML

July 5, 2024

BAYER (SOUTH EAST ASIA) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAYER (SOUTH EAST ASIA) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVITREOUS

Medical Information

S01LA05

Manufacturer Information

BAYER (SOUTH EAST ASIA) PTE LTD

Catalent Indiana, LLC

Active Ingredients

Aflibercept

114.3mg/ml

Aflibercept

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EYLEA SOLUTION FOR INJECTION 114.3 MG/ML - HSA Approval | MedPath